Korean J Hepatol > Volume 14(4); 2008 > Article
The Korean Journal of Hepatology 2008;14(4): 513-518.
doi: https://doi.org/10.3350/kjhep.2008.14.4.513
A case report of treatment with pegylated interferon alpha for Lamivudine-resistant chronic hepatitis B virus infection
Won Haing Hur , Hyun Young Woo , Soung Won Jeong , Chan Ran You , Si Hyun Bae , Jong Young Choi , Seung Kew Yoon
Department of Internal Medicine, College of Medicine, The Catholic University of Korea, WHO Collaborating Center of Viral Hepatitis, Seoul, Korea
The wide use of lamivudine in chronic hepatitis B has produced a monotonic increase in patients with lamivudine resistance. Therefore, treating lamivudine resistance in chronic hepatitis B is a major concern in clinical practice for the treatment of hepatitis B virus (HBV). There is conflicting evidence on the outcome of pegylated interferon alpha (PEG-IFN α) therapy against lamivudine-resistant HBV, which is due to mutations in the YMDD motif. We experienced a patient with chronic hepatitis B who was successfully treated with PEG-IFN α-2a after the development of virologic and biochemical breakthrough during lamivudine therapy. Virologic breakthrough was associated with the emergence of YMDD mutants 48 months after starting lamivudine therapy. Treatment with PEG-IFN α-2a for 12 months resulted in an undetectable serum level of HBV DNA and the resolution of hepatitis, and the virologic response was maintained over 16 months after cessation of PEG-IFN α-2a. (Korean J Hepatol 2008;14:513-518)
KeyWords: Pegylated interferon alfa-2a; Lamivudine; YMDD motif mutant; Hepatitis B, Chronic

Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: kasl@kams.or.kr
Copyright © The Korean Association for the Study of the Liver.         
TODAY : 748
TOTAL : 1777894
Close layer